1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Toxoplasmosis - Overview
- Toxoplasmosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Toxoplasmosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Toxoplasmosis - Companies Involved in Therapeutics Development
- AbbVie Inc
- GlaxoSmithKline Plc
- Tiba Biotech LLC
- Vaxinano SE
- Vyera Pharmaceuticals LLC
- Toxoplasmosis - Drug Profiles
- fanotaprim - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibodies for Ocular Toxoplasmosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pyrimethamine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pyrimethamine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pyrimethamine formulation I - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules for Toxoplasmosis - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- toxoplasmosis [type II delta KU80 RH strain] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- toxoplasmosis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- toxoplasmosis vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TRP-012 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TUR-006 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Toxoplasmosis - Dormant Projects
- Toxoplasmosis - Product Development Milestones
- Featured News & Press Releases
- Apr 15, 2020: Oakrum Pharma announces the launch of Toxo Total Care patient services program to support Pyrimethamine 25mg tablets
- Mar 31, 2020: Optime Care announces availability Of 25mg Pyrimethamine tablets for patients diagnosed with toxoplasmosis
- Mar 11, 2020: Oakrum Pharma announces the launch of Pyrimethamine 25mg tablets in the United States
- Feb 03, 2020: FDA grants approval of Daraprim drug’s first generic to Cerovene
- Jan 27, 2020: FTC and NY Attorney General charge Vyera Pharmaceuticals, Martin Shkreli, and other defendants with anticompetitive scheme to protect a list-price increase of more than 4,000 percent for life-saving drug Daraprim
- Nov 15, 2018: Vyera Pharmaceuticals receives FDA clearance to initiate a phase 1 study Of a new chemical entity designed as a potential treatment For toxoplasmosis
- Feb 08, 2018: Vyera Pharmaceuticals Has Initiated a Phase 1 Study of a New Dihydrofolate Reductase Inhibitor Designed as a Potential Treatment for Toxoplasmosis
- Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee
- Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing
- Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)
- Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary
- Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability
- Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging
- Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction
- Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact
- Disclaimer
List of Tables
- Number of Products under Development for Toxoplasmosis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Toxoplasmosis - Pipeline by AbbVie Inc, H1 2020
- Toxoplasmosis - Pipeline by GlaxoSmithKline Plc, H1 2020
- Toxoplasmosis - Pipeline by Tiba Biotech LLC, H1 2020
- Toxoplasmosis - Pipeline by Vaxinano SE, H1 2020
- Toxoplasmosis - Pipeline by Vyera Pharmaceuticals LLC, H1 2020
- Toxoplasmosis - Dormant Projects, H1 2020
List of Figures
- Number of Products under Development for Toxoplasmosis, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- GlaxoSmithKline Plc
- Tiba Biotech LLC
- Vaxinano SE
- Vyera Pharmaceuticals LLC
